From Lewis Krauskopf: NEW YORK (Reuters) – U.S. healthcare investors have found success this year buying stocks of companies whose products improve eyesight, treat pets and fix crooked teeth, all viewed as unlikely to fall victim to political and regulatory issues pressuring a wide swath of the sector.
From BlackRock: As companies evolve, the way we classify them also needs to evolve. Martin Small and Jeff shen talk about how data science can help and why investors should care.
From BlackRock: With risks abounding in the markets, Russ Koesterich discusses the case for health care as a defensive sector.
Health care stocks have suffered as political rhetoric heats up around health care reform. BlackRock’s Heidi Richardson suggests the sector may have been over-penalized.
From BlackRock: This has been an unusual election in the United States, to say the least. Heidi Richardson discusses some of the potential investment implications as we head towards voting day.
Another quarter and another superb performance from pharmaceutical giant Johnson & Johnson (NYSE:JNJ). For the most part, healthcare ETFs have been performing in-line with the markets. Investors looking to avoid volatility tend to gravitate toward the big pharma plays.
NYSE:DOW, NYSE:AGN, CVE:MSC.H
NYSE:ABBV, NASDAQ:GILD, NYSE:JNJ
NYSEARCA:XLU, NYSEARCA:IYH, NYSEARCA:IYW
NASDAQ:GILD, NYSE:MRK, NYSE:BMY, NYSE:ABBV
NYSE:JNJ, NYSEARCA:XLV
NYSEARCA:XLV, NYSEARCA:VHT, NYSEARCA:IYH
NYSEARCA:XLV, NYSEARCA:IYH
NYSE:JNJ, NYSEARCA:XLV
NYSEARCA:IYH, NYSEARCA:XLF